Frontlight ResearchEarly access
CompletedNo phase
Longitudinal Observational Biomarker Study
Key facts
- Who runs it
- Centre for Addiction and Mental Health
- Where
- Los Angeles, New York, Pittsburgh, and St Louis, United StatesSee the 4 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- People taking part
- 506 people enrolled
- Started
- 27 Sept 2017
- Ended
- 31 Jul 2024
- Type of study
- Observational
- Treatments tested
- Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)
- Neuropsychological Data
- Clinical Scales
- Record updated
- 25 November 2024
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Men and women aged 60 and older
- Current Major Depressive Disorder (MDD)
- Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length
- Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher
Who cannot take part
- Dementia
- Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
- Non-correctable, clinically significant sensory impairment interfering with participation
- Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management
- Moderate to severe substance or alcohol use disorder
- Seizure disorder
- Parkinson's Disease
- High risk for suicide and unable to be managed safely in the clinical trial
- Individuals with any contraindications to MRI
Where in United States
Also in 1 other country, 1 site
- UCLA Late-Life Mood, Stress, and Wellness Research ProgramLos Angeles, United States
- Columbia University Adult and Late Life Depression ClinicNew York, United States
- UPMC Late-Life Depression, Evaluation, Prevention, and Treatment ProgramPittsburgh, United States
- Washington University School of Medicine Healthy Mind LabSt Louis, United States
About the trial
What the trial wants to find out
The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
Treatments tested
- Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)
- Neuropsychological Data
- Clinical Scales
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro Study)
- Record updated
- 25 November 2024